News on ERBB2 from BioPortfolio.com http://www.BioPortfolio.com Consolidated ERBB2 news from BioPortfolio.com Wed, 10 Feb 2010 08:35:21 GMT en Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Bhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033635&HITNO=0&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033635&THISHREF=http://c.moreover.com/click/here.pl%3fz2535298573%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033635&HITNO=0&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033635&THISHREF=http://c.moreover.com/click/here.pl%3fz2535298573%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comJournal of Clinical Oncology: Randomized study of lapatinib alone or in combination with trastuzumab in women with ERBB2-positive, trastuzumab-refractory metastatic breast cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4011568&HITNO=1&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4011568&THISHREF=http://c.moreover.com/click/here.pl%3fz2523001686%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4011568&HITNO=1&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4011568&THISHREF=http://c.moreover.com/click/here.pl%3fz2523001686%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4008334&HITNO=2&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4008334&THISHREF=http://c.moreover.com/click/here.pl%3fz2521507247%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4008334&HITNO=2&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4008334&THISHREF=http://c.moreover.com/click/here.pl%3fz2521507247%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comJournal of Clinical Oncology: Expansion for Glaxo's Tykerbhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997704&HITNO=3&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997704&THISHREF=http://c.moreover.com/click/here.pl%3fz2516832658%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997704&HITNO=3&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997704&THISHREF=http://c.moreover.com/click/here.pl%3fz2516832658%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Expansion For Glaxo?s Tykerbhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995309&HITNO=4&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995309&THISHREF=http://c.moreover.com/click/here.pl%3fz2515592032%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995309&HITNO=4&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995309&THISHREF=http://c.moreover.com/click/here.pl%3fz2515592032%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDaily Markets: GSKs Tykerb receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997145&HITNO=5&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997145&THISHREF=http://c.moreover.com/click/here.pl%3fz2516579233%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997145&HITNO=5&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997145&THISHREF=http://c.moreover.com/click/here.pl%3fz2516579233%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: GSK's TYKERB Receives Accelerated Approval For First-line Combination Treatment Of Hormone Receptor Positive, HER2+/ErbB2+ Breast Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987805&HITNO=6&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987805&THISHREF=http://c.moreover.com/click/here.pl%3fz2510082509%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987805&HITNO=6&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987805&THISHREF=http://c.moreover.com/click/here.pl%3fz2510082509%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: Medical News: GSK's TYKERB Receives Accelerated Approval For First-line Combination Treatment Of Hormone Receptor Positive, HER2+/ErbB2+ Breast Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987681&HITNO=7&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987681&THISHREF=http://c.moreover.com/click/here.pl%3fz2510032248%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987681&HITNO=7&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987681&THISHREF=http://c.moreover.com/click/here.pl%3fz2510032248%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: Breast cancer:http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3980336&HITNO=8&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3980336&THISHREF=http://c.moreover.com/click/here.pl%3fz2506328431%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3980336&HITNO=8&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3980336&THISHREF=http://c.moreover.com/click/here.pl%3fz2506328431%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comLancet: Breast Cancer Therapy: Researchers from Cold Spring Harbor Laboratory provide details of new studies and findings in the area of breast cancer therapyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3968330&HITNO=9&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3968330&THISHREF=http://c.moreover.com/click/here.pl%3fz2500303895%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3968330&HITNO=9&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3968330&THISHREF=http://c.moreover.com/click/here.pl%3fz2500303895%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Roche invests in production of new Herceptin formulationhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3959658&HITNO=10&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3959658&THISHREF=http://c.moreover.com/click/here.pl%3fz2495829102%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3959658&HITNO=10&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3959658&THISHREF=http://c.moreover.com/click/here.pl%3fz2495829102%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmafocus: Breast Cancer Therapy - Researchers from Cold Spring Harbor Laboratory provide details of new studies and findhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3952640&HITNO=11&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3952640&THISHREF=http://c.moreover.com/click/here.pl%3fz2490924046%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3952640&HITNO=11&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3952640&THISHREF=http://c.moreover.com/click/here.pl%3fz2490924046%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Breast Cancer - Research from S. Saglam and co-researchers in the area of breast cancer publishedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3952702&HITNO=12&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3952702&THISHREF=http://c.moreover.com/click/here.pl%3fz2490929000%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3952702&HITNO=12&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3952702&THISHREF=http://c.moreover.com/click/here.pl%3fz2490929000%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Carcinoma in Situ Genetics: Research from Oregon Health & Science University, Cancer Institute provides new data about carcinoma in situ geneticshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3939288&HITNO=13&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3939288&THISHREF=http://c.moreover.com/click/here.pl%3fz2484565382%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3939288&HITNO=13&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3939288&THISHREF=http://c.moreover.com/click/here.pl%3fz2484565382%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarityhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3912640&HITNO=14&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3912640&THISHREF=http://c.moreover.com/click/here.pl%3fz2470311715%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3912640&HITNO=14&MSIZE=26&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ERBB2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3912640&THISHREF=http://c.moreover.com/click/here.pl%3fz2470311715%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comOncogene Journal: